Although statistical significance was not reached in that study due to the relatively small sample size, we still observed an elevation of serum APE1 (from hereon referred to as sAPE1) levels in NSCLC patients associated with advanced stages of the disease. Here, APEX1 is linked to non-small cell lung carcinoma.